139 related articles for article (PubMed ID: 9542792)
1. Prolactin response to D-fenfluramine challenge test as a predictor of treatment response to haloperidol in acute schizophrenia.
Mohr P; Horácek J; Motlová L; Libiger J; Czobor P
Schizophr Res; 1998 Feb; 30(1):91-9. PubMed ID: 9542792
[TBL] [Abstract][Full Text] [Related]
2. Effects of haloperidol treatment on prolactin response to D-fenfluramine challenge in acute schizophrenia.
Mohr P; Horácek J; Motlová L; Libiger J; Czobor P
Psychopharmacology (Berl); 1999 Jan; 141(3):322-5. PubMed ID: 10027514
[TBL] [Abstract][Full Text] [Related]
3. Risperidone is associated with blunting of D-fenfluramine evoked serotonergic responses in schizophrenia.
Jones H; Curtis VA; Wright PA; Lucey JV
Int Clin Psychopharmacol; 1998 Sep; 13(5):199-203. PubMed ID: 9817624
[TBL] [Abstract][Full Text] [Related]
4. D-fenfluramine-evoked serotonergic responses in olanzapine-treated schizophrenic patients.
Jones H; Curtis VA; Wright P; Pilowsky LS; Lucey JV
Psychiatry Res; 2002 Dec; 113(1-2):41-7. PubMed ID: 12467944
[TBL] [Abstract][Full Text] [Related]
5. Neuroendocrine serotonergic and dopaminergic responsivity in male schizophrenic patients during treatment with neuroleptics and after switch to risperidone.
Markianos M; Hatzimanolis J; Lykouras L
Psychopharmacology (Berl); 2001 Aug; 157(1):55-9. PubMed ID: 11512043
[TBL] [Abstract][Full Text] [Related]
6. Prolactin hyperresponsiveness to D-fenfluramine in drug-free schizophrenic patients: a placebo-controlled study.
Monteleone P; Tortorella A; Borriello R; Cassandro P; Maj M
Biol Psychiatry; 1999 Jun; 45(12):1606-11. PubMed ID: 10376122
[TBL] [Abstract][Full Text] [Related]
7. Dopamine and serotonin function in untreated schizophrenia: clinical correlates of the apomorphine and d-fenfluramine tests.
Duval F; Mokrani MC; Monreal J; Bailey P; Valdebenito M; Crocq MA; Macher JP
Psychoneuroendocrinology; 2003 Jul; 28(5):627-42. PubMed ID: 12727131
[TBL] [Abstract][Full Text] [Related]
8. The prolactin response to fenfluramine in schizophrenia is associated with negative symptoms.
Sharma RP; Singh V; Janicak PG; Javaid JI; Pandey GN
Schizophr Res; 1999 Aug; 39(1):85-9. PubMed ID: 10480671
[TBL] [Abstract][Full Text] [Related]
9. Dopamine receptor responsivity in schizophrenic patients before and after switch from haloperidol to risperidone.
Markianos M; Hatzimanolis J; Lykouras L
Psychiatry Res; 1999 Dec; 89(2):115-22. PubMed ID: 10646830
[TBL] [Abstract][Full Text] [Related]
10. Neuroendocrine evidence that clozapine's serotonergic antagonism is relevant to its efficacy in treating hallucinations and other positive schizophrenic symptoms.
Jones H; Curtis VA; Wright P; Lucey JV
Am J Psychiatry; 1998 Jun; 155(6):838-40. PubMed ID: 9619161
[TBL] [Abstract][Full Text] [Related]
11. Serotonin transporter promoter polymorphism is associated with attenuated prolactin response to fenfluramine.
Reist C; Mazzanti C; Vu R; Tran D; Goldman D
Am J Med Genet; 2001 May; 105(4):363-8. PubMed ID: 11378851
[TBL] [Abstract][Full Text] [Related]
12. Effect of clozapine on d-fenfluramine-evoked neuroendocrine responses in schizophrenia and its relationship to clinical improvement.
Curtis VA; Wright P; Reveley A; Kerwin R; Lucey JV
Br J Psychiatry; 1995 May; 166(5):642-6. PubMed ID: 7620750
[TBL] [Abstract][Full Text] [Related]
13. Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: a placebo-controlled trial.
Shim JC; Shin JG; Kelly DL; Jung DU; Seo YS; Liu KH; Shon JH; Conley RR
Am J Psychiatry; 2007 Sep; 164(9):1404-10. PubMed ID: 17728426
[TBL] [Abstract][Full Text] [Related]
14. 5-HT3 receptor antagonism by ondansetron does not attenuate prolactin response to d-fenfluramine challenge in healthy human subjects.
Coccaro EF; Kavoussi RJ; Cooper TB; Hauger R
Psychopharmacology (Berl); 1996 Sep; 127(2):108-12. PubMed ID: 8888375
[TBL] [Abstract][Full Text] [Related]
15. A practical clinical trial comparing haloperidol, risperidone, and olanzapine for the acute treatment of first-episode nonaffective psychosis.
Crespo-Facorro B; Pérez-Iglesias R; Ramirez-Bonilla M; Martínez-García O; Llorca J; Luis Vázquez-Barquero J
J Clin Psychiatry; 2006 Oct; 67(10):1511-21. PubMed ID: 17107241
[TBL] [Abstract][Full Text] [Related]
16. Enhancement of the prolactin response to d-fenfluramine in drug-naive schizophrenic patients.
Abel KM; O'Keane V; Murray RM
Br J Psychiatry; 1996 Jan; 168(1):57-60. PubMed ID: 8770429
[TBL] [Abstract][Full Text] [Related]
17. Haloperidol. Plasma levels and prolactin response as predictors of clinical improvement in schizophrenia: chemical v radioreceptor plasma level assays.
Smith RC; Baumgartner R; Misra CH; Mauldin M; Shvartsburd A; Ho BT; DeJohn C
Arch Gen Psychiatry; 1984 Nov; 41(11):1044-9. PubMed ID: 6497566
[TBL] [Abstract][Full Text] [Related]
18. Plasma oxytocin in response to pharmaco-challenge to D-fenfluramine and placebo in healthy men.
Lee R; Garcia F; van de Kar LD; Hauger RD; Coccaro EF
Psychiatry Res; 2003 May; 118(2):129-36. PubMed ID: 12798977
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder.
Kane JM; Carson WH; Saha AR; McQuade RD; Ingenito GG; Zimbroff DL; Ali MW
J Clin Psychiatry; 2002 Sep; 63(9):763-71. PubMed ID: 12363115
[TBL] [Abstract][Full Text] [Related]
20. Lack of effect of hydrocortisone treatment on d-fenfluramine-mediated prolactin release.
Young AH; Rue J; Odontiadis J; Cowen PJ
Psychopharmacology (Berl); 1998 Mar; 136(2):198-200. PubMed ID: 9551777
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
